{
    "title": "106_hr1039",
    "content": "CREDIT FOR CLINICAL TESTING RESEARCH EXPENSES ATTRIBUTABLE TO QUALIFIED ACADEMIC INSTITUTIONS INCLUDING TEACHING HOSPITALS. Amendment to the Internal Revenue Code of 1986 to include a new section 41A for a credit for medical innovation expenses. The medical innovation credit under section 38 allows for a 20 percent credit on qualified medical innovation expenses exceeding the medical innovation base period amount. Qualified expenses include payments to qualified academic institutions for clinical testing research activities before product approval. The term 'research activities' refers to human clinical testing conducted at qualified academic institutions in the development of any drug, biologic, or medical device before product approval. A qualified academic institution is defined as specific institutions involved in such research activities. The term 'product' under the Federal Food, Drug, and Cosmetic Act includes drugs, biologics, and medical devices. A 'qualified academic institution' is defined as an educational institution, teaching hospital, or medical research organization affiliated with certain criteria. The term 'qualified medical innovation expenses' excludes funding from grants or contracts. The 'medical innovation base period amount' is defined for this section. The term 'qualified medical innovation expenses' does not include funding from grants, contracts, or other sources. The 'medical innovation base period amount' is the average annual expenses incurred by the taxpayer in the three years before the first taxable year after December 31, 1998. Special rules apply, including limitations on foreign testing and the need for taxpayer election for this section to apply. Certain rules similar to subsections (f) and (g) of section 41 apply for this section. Taxpayers must elect for this section to apply for a taxable year. Any qualified medical innovation expense under this section cannot be used to determine the credit under section 41 or 45C. This section does not apply to expenses paid after the specified date in section 41(h)(1)(B). The credit is part of the general business credit under section 38(b) of the tax code. The medical innovation expenses credit is part of the general business credit under section 38(b) of the tax code. No portion of the unused business credit attributable to the medical innovation credit can be carried back before January 1, 1999. Additionally, there is a denial of double benefit for increasing medical innovation expenses. The medical innovation credit can be carried back to a taxable year before January 1, 1999. No deduction is allowed for qualified medical innovation expenses equal to the credit determined under section 41A. Rules similar to subsection (c) apply. Unused portion of the credit can be deducted under section 196(c) of the tax code. The medical innovation expenses credit under section 41A can be carried back to a taxable year before January 1, 1999. No deduction is allowed for qualified medical innovation expenses equal to the credit determined under section 41A. Rules similar to subsection (c) apply. Unused portion of the credit can be deducted under section 196(c) of the tax code. The amendments made by section 41A for the credit for medical innovation expenses will apply to taxable years starting after December 31, 1998."
}